Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

The New England Journal of Medicine
R S SperlingJ L Sullivan

Abstract

A placebo-controlled trial has shown that treatment with zidovudine reduces the rate at which human immunodeficiency virus type 1 (HIV-1) is transmitted from mother to infant. We present data from that trial showing the number of infected infants at 18 months of age and the relation between the maternal viral load, the risk of HIV-1 transmission, and the efficacy of zidovudine treatment. Viral cultures were obtained, and HIV-1 RNA was measured by two assays in samples of maternal blood obtained at study entry and at delivery. In 402 mother-infant pairs, the rate of transmission of HIV-1 was 7.6 percent (95 percent confidence interval, 4.3 to 12.3 percent) with zidovudine treatment and 22.6 percent (95 percent confidence interval, 17.0 to 29.0 percent) with placebo (P<0.001). In the placebo group, a large viral burden at entry or delivery or a positive culture was associated with an increased risk of transmission (the transmission rate was greater than 40 percent in the highest quartile of the RNA level). In both groups, transmission occurred at a wide range of maternal plasma HIV-1 RNA levels. Zidovudine reduced plasma RNA levels somewhat (median reduction, 0.24 log). Zidovudine was effective regardless of the HIV-1 RNA level o...Continue Reading

References

Jan 30, 1992·Statistics in Medicine·L S FreedmanA Schatzkin
May 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L M FrenkelR C Reichman
Jun 22, 1994·JAMA : the Journal of the American Medical Association·P J BoyerY J Bryson
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·G FangB Weiser
May 15, 1996·JAMA : the Journal of the American Medical Association·S A FiscusC Wilfert

❮ Previous
Next ❯

Citations

Mar 13, 1998·Journal of Medical Virology·S O'SheaJ E Banatvala
Apr 25, 2000·Teratology·W SlikkerM C Poirier
Apr 15, 2004·Indian Journal of Pediatrics·Anju KapoorShashi N Vani
Feb 26, 2004·Indian Journal of Pediatrics·Chokechai Rongkavilit, Basim I Asmar
Nov 4, 2000·Archives of Pharmacal Research·R Samuel, B Suh
Nov 30, 2000·Current Infectious Disease Reports·M J Kuehnert, D M Cardo
Jul 27, 2001·Current Infectious Disease Reports·Jaime Deville, Yvonne Bryson
Apr 6, 2012·Immunologic Research·Benjamin K Chen
Jun 11, 2005·Early Human Development·Gian Maria Pacifici
Jun 25, 2013·Human Immunology·Taissa M KasaharaCleonice A M Bento
May 19, 2005·Social Science & Medicine·Kristine HopkinsJoseph E Potter
May 19, 1997·The American Journal of Medicine·D M Bell, J L Gerberding
Jan 12, 1999·Disease-a-month : DM·H W HorowitzG P Wormser
Nov 14, 1998·Disease-a-month : DM·H W HorowitzG P Wormser
Jan 1, 1999·Journal of Nurse-midwifery·A MacLaren, W Imberg
Dec 30, 1999·Annals of Emergency Medicine·G J Moran
May 20, 2003·Social Science & Medicine·Susan Kippax, Kane Race
Jun 27, 1998·European Journal of Obstetrics, Gynecology, and Reproductive Biology·V PuroG Ippolito
Apr 28, 2000·Early Human Development·C Thorne, M L Newell
Jan 15, 2000·Journal of Substance Abuse Treatment·P G O'Connor
Jan 6, 2001·Infectious Disease Clinics of North America·M E Blocker, M S Cohen
Jul 1, 1998·Clinical and Diagnostic Virology·R L Hodinka
Feb 9, 1999·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·V del BonoR D'Amelio
May 25, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Elizabeth Secord, Cristina Cotronei-Cascardo
Jun 1, 1997·Molecular Medicine Today·A J Melvin, L M Frenkel
Feb 13, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·A BergerH W Doerr
Jun 22, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·G KamkamidzeT Charbonneau
Jul 20, 2002·The Lancet Infectious Diseases·Jia-Horng Kao, Ding-Shinn Chen
Jan 11, 2002·Journal of Midwifery & Women's Health·L Patchen, M W Beal
Mar 17, 2001·Scandinavian Journal of Immunology·V BongertzM G Morgado
Aug 12, 2000·Journal of Paediatrics and Child Health·B a OlayinkaF E Mbajiorgu
Nov 28, 1996·The New England Journal of Medicine·C M Wilfert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.